Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Intercept Pharma down 11% ahead of update on Phase 3 REGENERATE Trial of Obeticholic Acid for the treatment of NASH patients with Liver Fibrosis at 8:30 (112.69)<ul><li>ICPT may get halted here around the release… stock is testing 2016 lows near 100 premarket.</li><li>NASH is non-alcoholic fatty liver disease.<ul><li>NASH stocks: <strong>GLMD</strong>, <strong>GALT</strong>, <strong>GNFTF</strong>, <strong>CNAT</strong>; <strong>AGN</strong> acquired NASH company TBRA last year</li></ul></li></ul></td> </tr></table>"